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Introduction
Benign prostatic hyperplasia (BPH) is a highly preva-
lent disorder that affects approximately 50% of men
aged 65 years and older and is associated with lower
urinary tract symptoms (LUTS) (1). The cluster of
BPH-related LUTS, which include nocturia, fre-
quency, urgency, hesitancy, intermittency and incom-
plete emptying, can negatively impact health-related
quality of life (2,3). BPH can also lead to more seri-
ous complications, such as acute urinary retention,
urinary tract infections, long-term renal insufﬁciency,
and haematuria (4). The initial assessment of
BPH⁄LUTS involves symptom assessment which
ideally includes administration of the seven-item
American Urological Association symptom index
(AUA-SI), which evaluates the presence and severity
of the main components of LUTS (2). These seven
questions have been internationally adopted, with
the addition of an eighth question related to bother,
as the International Prostate Symptom Score
(IPSS) (2).
The AUA recommends a1-adrenergic receptor
blockers (A1Bs) as safe and efﬁcacious pharmaco-
logic treatment options for patients suffering from
BPH (2). A1Bs block the adrenergic receptors, which
are abundant in the smooth muscle of the prostate
and bladder, produces a reduction in smooth muscle
tone (5). Of the three A1B subtypes (a1A, a1B and
a1D), a1A is seen as the primary regulator of smooth
muscle tone in the bladder neck and prostate (6,7).
In contrast, the a1B subtype regulates blood pressure
via arterial smooth muscle relaxation, while the a1D
subtype is associated with contraction of the bladder
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SUMMARY
Objectives: To evaluate the safety proﬁle and efﬁcacy of a1-adrenergic receptor
blockers (A1Bs) currently prescribed for benign prostatic hyperplasia (BPH). Data
sources: A systematic literature search of MEDLINE, the Cochrane Database and
the Food and Drug Administration Web site through December 2006 identiﬁed
double-blinded, prospective, placebo-controlled trials, evaluating agents commer-
cially available by prescription for the symptomatic treatment of BPH. Review
methods: Data were reviewed by two investigators with the use of a standardised
data abstraction form. Studies were evaluated for methodological quality using the
Jadad scale. Studies with a score of < 3 were considered of weaker methodology.
Results: Of 2389 potential citations, 25 were usable for evaluation of safety data,
26 for efﬁcacy. A1B use was associated with a statistically signiﬁcant increase in
the odds of developing a vascular-related event [odds ratio (OR) 2.54; 95% conﬁ-
dence interval (CI): 2.00–3.24; p < 0.0001]. The odds of developing a vascular-
related adverse event were: alfuzosin, OR 1.66, 95% CI: 1.17–2.36; terazosin, OR
3.71, 95% CI: 2.48–5.53; doxazosin, OR 3.32, 95% CI: 2.10–5.23 and tamsulo-
sin, OR 1.42, 95% CI: 0.99–2.05. A1Bs increased Qmax by 1.32 ml⁄min (95% CI:
1.07–1.57) compared with placebo. Difference from placebo in American Urologi-
cal Association symptom index⁄International Prostate Symptom Score was )1.92
points (95% CI: )2.71 to )1.14). Conclusions: Alfuzosin, terazosin and doxazo-
sin showed a statistically signiﬁcant increased risk of developing vascular-related
events compared with placebo. Tamsulosin showed a numerical increase that was
not statistically signiﬁcant. All agents signiﬁcantly improved Qmax and symptom
signs compared with placebo.
What’s known
The four most frequently prescribed a1-adrenergic
receptor blockers (A1Bs) (alfuzosin, terazosin,
doxazosin including the GITS formulation and
tamsulosin) are all effective in relieving the
symptoms of benign prostatic hyperplasia (BPH).
However, it is also known that these four agents
vary in their subtype selectivity and are associated
with differing side effect proﬁles. Meta-analysis to
determine the safety-related adverse event proﬁle
of the A1Bs has been performed in the past, but
newer treatment practices and new formulations of
older agents may invalidate these prior analyses.
What’s new
This meta-analysis shows that the A1Bs alfuzosin,
terazosin, doxazosin and doxazosin GITS statistically
signiﬁcantly increased the risk of developing
vascular-related adverse events compared with
placebo. Tamsulosin, an A1B with subtype
selectivity to the a-1A and a-1D, showed a
numerical increase in risk that was not statistically
signiﬁcant compared with placebo. All agents
signiﬁcantly improved Qmax and symptom score
compared with placebo.
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(6–8).
The four most frequently prescribed A1Bs – teraz-
osin, doxazosin [also available as doxazosin gastroin-
testinal therapeutic system (GITS)], alfuzosin and
tamsulosin – vary in their subtype selectivity and are
associated with differing side effect proﬁles (2).
Because a-blockers cause vasodilation, vascular-
related adverse events take the form of dizziness, pre-
syncope or syncope. These symptoms can be life
threatening, particularly in an older patient popula-
tion. Terazosin and doxazosin, originally developed
as antihypertensive drugs, are non-subtype-selective
A1Bs, and both are associated with a larger number
of vasodilatory side effects than either tamsulosin or
alfuzosin (9–12). Both terazosin and doxazosin
require titration in order to reduce the risk of vasod-
ilatory side effects. While alfuzosin is also a non-sub-
type-selective A1B, it is considered uroselective; it is
associated with fewer vasodilatory adverse events and
does not require titration (13–15). Tamsulosin differs
from the other A1Bs in that it is selective for the a1A
and a1D subtypes (16). Tamsulosin is associated with
a low incidence of vasodilatory side effects and does
not require titration (17,18).
The present meta-analysis was conducted to assess
vascular-related adverse events and efﬁcacy among
four available A1Bs used to treat BPH⁄LUTS.
Because vascular-related adverse events constitute the
only category of BPH treatment-related adverse
events that have the potential to be life threatening,
this study focuses on these events. Although meta-
analyses of this nature have been done in the past,
such studies may no longer accurately account for
current BPH treatment practices. The recent develop-
ment of newer dosing formulations (including
extended-release formulations) of the available BPH
medications may provide superior safety compared
with the earlier selection of formulations, and while
earlier studies analyzed each respective compound
taken as a whole (i.e. without regard to differences
between formulations), this study evaluates only the
speciﬁc formulation and doses of each BPH medica-
tion currently used.
Methods
Study Selection
Studies evaluated in this meta-analysis were derived
from a literature search of MEDLINE from 1966
through December 2006, the Cochrane Database, and
the Food and Drug Administration (FDA) web site.
An optimally sensitive search strategy was employed
to identify randomised trials (19). Additionally, a
manual search of references from identiﬁed clinical
trials and review articles, as well as relevant presenta-
tions pertaining to BPH, were performed. Key words
included ‘benign prostatic hyperplasia’, ‘BPH’,
‘alpha-1 adrenergic receptor antagonist’, ‘terazosin’,
‘doxazosin’, ‘tamsulosin’, ‘alfuzosin’, ‘safety’, ‘adverse
event’ and ‘efﬁcacy’. All searches were limited to
clinical trials in human subjects and reports pub-
lished in English. Inclusion criteria for studies in this
analysis required that they be double-blinded, pro-
spective, placebo-controlled trials evaluating agents
commercially available by prescription for the symp-
tomatic treatment of BPH. Trials that were per-
formed with immediate-release alfuzosin were
excluded, as that formulation is not available. Alfuz-
osin trials were limited to those that use the current
controlled-release formulation. Included trials also
had to evaluate one of the meta-analysis outcome
measures described below.
Outcome measures
The primary outcome measure was the odds of expe-
riencing a vascular-related adverse event among
A1Bs, deﬁned as the occurrence of one of the follow-
ing: dizziness, hypotension or syncope. Other out-
comes included: (i) adverse events potentially related
to the effect of A1Bs on peripheral vasculature
including asthenia, fatigue and headache, (ii) efﬁcacy
of A1Bs based on change from baseline of maximum
urinary ﬂow rate (Qmax) and change from baseline of
AUA-SI or IPSS. Only those events reported in the
trials as adverse events, and not actively sought after,
were evaluated (e.g. patients who met a predeter-
mined change in systolic blood pressure upon stand-
ing were not considered for this analysis as having
hypotension, whereas patients who reported hypo-
tension outside the physician’s ofﬁce were).
Validity assessment and data abstraction
All data were reviewed by two investigators with the
use of a standardised data abstraction form. The
included studies were evaluated for methodological
quality using the Jadad scale (20). Studies with a
score of < 3 were considered of weaker methodology.
For each study, the following data were collected:
authorship, year of publication, mean age, length of
treatment, entry criteria, prostate size, average dose,
appropriate use of randomisation, random allocation
concealment, masking of treatment allocation and
blinding, sample size, total per cent of patients dis-
continued, per cent of patients withdrawn because of
adverse event, speciﬁc A1Bs and dose, type of adverse
event and raw incidence data or odds ratio (OR) and
95% conﬁdence interval (CI), change in IPSS⁄AUA
and Qmax and weighted mean difference (WMD)
from placebo.
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For the safety evaluation, outcome measures were
dichotomous and expressed in terms of pooled OR
relative to placebo with accompanying 95% CIs.
Analysis of A1B safety and efﬁcacy was based on the
intention-to-treat population for each given trial.
Analyses were conducted using StatsDirect statistical
software version 2.4.5 (Stats-Direct Ltd, Cheshire,
UK) using random-effects model (DerSimonian and
Laird methodology). p < 0.05 was considered statisti-
cally signiﬁcant. Statistical heterogeneity of the pri-
mary end-point was measured using the Cochrane’s
Q statistic (p < 0.1 was considered to represent het-
erogeneity).
To establish the effect of clinical heterogeneity
between studies on our meta-analysis’ conclusions,
subgroup analysis was conducted. As the effect of
A1Bs may vary, the impact of individual A1B use on
the odds of developing a vascular-related adverse
event was evaluated.
For the efﬁcacy evaluation, change in Qmax and
change in symptom scores were expressed as WMD
from baseline with accompanying 95% CIs. Changes
from baseline were compared between treatment and
placebo and expressed as the difference (treat-
ment ) control) of the changes (baseline ) follow-
up) in these mean values. In studies in which the
variance of changes was not reported directly, vari-
ances were calculated from CIs, t-statistics, p-values
or individual variances for intervention and control
groups (parallel trials). For trials in which variance
of paired differences was reported separately for each
group, a pooled variance for net change was calcu-
lated by standard methods. When the variance for
paired differences was not reported, it was calculated
from variances at baseline and at the end of follow-
up. A correlation coefﬁcient of 0.5 between initial
and ﬁnal values was assumed (21). Additionally,
equal variances were assumed during the trial and
between intervention and control groups.
Studies evaluating tamsulosin used a dose of
0.4 mg, and studies evaluating alfuzosin used a dose
of 10 mg daily. The evaluated doses for doxazosin
ranged from 2–8 mg⁄day, for doxazosin GITS from
4t o8 m g ⁄day, and for terazosin from 1 to
10 mg⁄day. Patients on terazosin or doxazosin were
either titrated based on response or randomly
assigned a predetermined ﬁxed dose.
Publication bias was assessed using several meth-
ods. Visual inspection of a funnel plot for vascular-
related end-points was performed. A funnel plot pro-
vides a visual representation of each study included
in the meta-analysis plotted by its effect size on the
horizontal axis and variance on the vertical axis.
When publication bias is not present, the funnel plot
resembles an inverted funnel, with less precise studies
having greater variance scattered at the bottom to
either side of the more precise studies. If publication
bias is present in a meta-analysis, the plot does not
appear as an inverted, symmetrical funnel. The Eg-
ger’s weighted regression method was also used to
assess publication bias (p < 0.05 was considered rep-
resentative of statistically signiﬁcant publication bias)
(22).
Results
Study characteristics
Our initial search yielded 2389 potential citations, of
which 2360 were excluded for reasons presented in
Figure 1. Table 1 provides an overview of the com-
posite baseline characteristics of all trials included in
the meta-analyses, including entry criteria, treatment
dosages, discontinuation rates and Jadad scores
(9–11,17,18,23–45). With regard to entry criteria,
there was an overall similarity between A1B trials.
Patient enrolment for A1B trials ranged from 30 to
1053 patients, and the mean age ranged from 58 to
68 years. A total of 25 studies evaluated safety data
and 26 studies reported efﬁcacy data among A1Bs.
The studies evaluated alfuzosin (n = 4), tamsulosin
(n = 8), terazosin (n = 7), doxazosin GITS (n =2 )
and doxazosin (n = 8). The treatment duration of
the A1B trials most commonly ranged from 4 to
24 weeks, although several trials lasted 1 or 2 years
and in one case lasted for 4.5 years.
Quantitative data synthesis
Safety
Figure 2 presents ORs and 95% CIs for each trial
and the overall combined primary end-point of the
vascular-related adverse event. A1Bs were associated
with a statistically signiﬁcant increase in the odds of
developing a vascular-related adverse event relative
to placebo. (OR 2.54; 95% CI: 2.00–3.23;
p < 0.0001). Heterogeneity could not be ruled out
through Cochrane’s Q statistic (p = 0.011). Publica-
tion bias was not evident with review of the funnel
plot (Figure 3) or Egger’s weighted regression
(p = 0.63).
Subgroup analysis was conducted, and the results
are depicted in Figure 4 and Table 2. When A1Bs
were evaluated individually, differences in vascular-
related adverse events were observed. There was a
signiﬁcantly higher odds of developing the primary
composite end-point relative to placebo for alfuzosin
(p = 0.005), terazosin (p < 0.0001), doxazosin
a1-adrenergic receptor blockers in benign prostatic hyperplasia 1549
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odds of developing a vascular event was higher with
tamsulosin relative to placebo, but the difference was
not statistically signiﬁcant (p = 0.053). Statistical het-
erogeneity was not present for alfuzosin, terazosin
and tamsulosin (Q-statistic p >0.1); however, statisti-
cal heterogeneity could not be ruled out for doxazo-
sin (Q-statistic p = 0.039).
Efﬁcacy
Qmax for all A1Bs improved by 1.32 ml⁄min (95%
CI: 1.07–1.57; p < 0.0001). The WMD in AUA-
SI⁄IPSS for all A1Bs was )1.92 points (95% CI,
)2.71 to )1.14); p < 0.0001). Individual differences
from placebo in efﬁcacy are reported in Table 3, and
individual A1B results for Qmax are presented in
Figure 5.
Discussion
The present meta-analysis of A1Bs in the treatment
of BPH and its related symptoms is, to our
knowledge, the most complete of its kind to date.
The results demonstrate that the use of A1Bs in
BPH treatment confers an added risk of vascular-
related adverse events compared with placebo. The
exception to this ﬁnding was that tamsulosin,
although associated with a trend toward greater
odds of experiencing a vascular-related adverse
event, was not statistically signiﬁcantly different
from placebo.
The occurrence of vasodilatory side effects among
patients using A1Bs for the treatment of BPH⁄LUTS
may be related to the speciﬁc selectivity proﬁle for
a-adrenergic receptor subtypes of each individual
agent (8). Of the three known a-adrenergic receptors
– a1A, a1B and a1D–a1A is predominant in the pros-
tate, while the a1B subtype is localised in the periph-
eral vasculature, and the a1D-receptor subtype is
expressed in the bladder and spinal cord (6–8). Ter-
azosin and doxazosin are long-acting, non-subtype-
selective A1Bs, both of which were initially developed
and marketed as antihypertensive agents. This non-
selectivity and propensity to induce vascular-related
effects has been demonstrated, in that both drugs,
when used at therapeutic levels, are associated with
an increased risk for hypotension and dizziness
(9,12,38). Indeed, the results of this meta-analysis
reﬂect the heightened odds for experiencing both of
these side effects, as well as increased risk for vascu-
lar-related side effects overall, with terazosin and
doxazosin treatment. Doxazosin GITS is a controlled
release formulation of doxazosin that reduces the
peak-to-trough ratio minimising the need for titra-
tion (40). Nevertheless, the odds of experiencing a
vascular event are similar to those of non-subtype-
selective A1Bs. Alfuzosin is also non-subtype-selec-
tive. This may account for the observed increase in
the odds for an adverse vascular event with alfuzosin
treatment (7,8). Tamsulosin is much more selective
at a1A and a1D receptors than at a1B receptors (46).
Tamsulosin’s low risk of vasodilatory effects, as
2322 Citations excluded
1275  Not controlled clinical trial 
375  Not published in English
2389 Citations identified and 
screened
pg
576  No usable end point
76  Evaluated 5-alpha reductase inhibitors
20  Not human studies   67 Abstracts retrieved for detailed 
evaluation
35 Abstracts excluded
20 No usable end point
15 Evaluated 5-alpha reductase inhibitors  32 Full-text articles retrieved for 
3 Articles excluded
2  Not double-blinded trial
1  Not placebo-controlled trial  
review
29 Studies included
4   Reported alfuzosin
8   Reported tamsulosin
7   Reported terazosin
2 Reported doxazosin GITS
8   Reported doxazosin  
Figure 1 Flow chart for study selection
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the result of its subtype receptor selectivity. It is
most likely because of these pharmacological differ-
ences of agents that statistical heterogeneity among
trials could not be ruled out for any agent for the
primary end-point. Upon subgroup analyses of trials
of individual agents, however, statistical heterogene-
ity was not present for any agent except doxazosin.
While the safety aspect of this meta-analysis is lim-
ited to vascular-related adverse events because of
their potentially life-threatening effects, it should be
noted that A1Bs are associated with other kinds of
adverse events, including those related to sexual
function. This adverse event may be a signiﬁcant dif-
ferentiating factor that physicians use to determine
which A1B treatment is optimal, particularly for
younger sexually active men with BPH. Tamsulosin
and terazosin are both associated with low but statis-
tically signiﬁcant increases in risk for abnormal ejac-
ulation compared with placebo (11,47,48). Most
studies of alfuzosin have observed no signiﬁcant
increase in risk of ejaculation disorder, although one
Roehrborn (ALFUS) 2001 (24) 3.17 (1.06, 11.36)
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Figure 2 The effect of a1-adrenergic receptor blockers on vascular-related adverse events. Sizes of the data markers are
indicative of the relative weight of each study. The bar is representative of the 95% conﬁdence interval
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S
t
a
n
d
a
r
d
 
e
r
r
o
r
Egger’s weighted
regression, p = 0.63
0.0
0.4
0.8
1.2
Log (odds ratio)
–3.0 –0.5 2.0 4.5
1.6
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no signiﬁcant difference between the two agents for
risk of abnormal ejaculation (47–49).
In terms of treatment efﬁcacy for BPH⁄LUTS,
this meta-analysis found no differences in improv-
ing Qmax and AUA-SI⁄IPSS symptom scores among
the different A1Bs compared with placebo. These
results are consistent with earlier meta-analyses
produced by the AUA Practice Guidelines Commit-
tee as well as by Djavan and Marberger (2,50).
Taking this into consideration, the preference
between A1Bs for the treatment of BPH⁄LUTS will
be necessarily contingent, at least in part, upon the
differing side effect proﬁles. This is particularly the
case for vascular-related side effects, as BPH⁄LUTS
disproportionately affects elderly patients who may
be more susceptible than younger patients to such
adverse events. Kaplan and Neutel underscored this
point in a recent publication, in which they rec-
ommended that clinicians keep themselves knowl-
edgeable about the latest clinical evidence for
differential risk of vasodilatory side effects between
Abrams 1995 (28)
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ALFOTAM – tamsulosin (25)
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Figure 4 Odds of developing a vascular-related adverse event while on speciﬁc a1-adrenergic receptor blockers. Sizes of
the data markers are indicative of the relative weight of each study. The bar is representative of the 95% conﬁdence
interval
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of an A1B with the lowest risk of vascular-related
adverse events is advisable for symptomatic older
patients in order to ensure safe and effective
BPH⁄LUTS treatment and to improve patient out-
comes (51).
A common limitation in undertaking meta-analy-
ses is the issue of publication bias, in which clinical
trials with statistically signiﬁcant results are published
and those with undesirable results frequently are not
(52). In conducting the present meta-analysis, an
attempt was made to avoid publication bias by seek-
ing out and including clinical trial data that have not
been previously published in peer-reviewed journals
(e.g. data from the FDA web site). Accordingly, pub-
lication bias was not present through visual inspec-
tion of the funnel plot or through Egger’s weighted
regression. Lastly, this meta-analysis could not rule
out heterogeneity through Cochrane’s Q-statistic.
However, upon further assessment with subgroup
analyses of trials of individual agents, statistical het-
erogeneity was not present for any agent except dox-
azosin.
Conclusions
The present meta-analysis sought to evaluate the
safety proﬁle and efﬁcacy of available pharmacologic
agents for BPH and its related symptoms. Alfuzosin,
terazosin, and doxazosin, and doxazosin GITS
showed a statistically signiﬁcant increased risk of
developing vascular-related events compared with
placebo, whereas tamsulosin showed a numerical
increase that was not statistically signiﬁcant. All
agents signiﬁcantly improved Qmax and symptom
score compared with placebo.
Kawabe 1990 (27)
ALFOTAM – tamsulosin (25)
Ab 199 (30) Abrams 1997 (30)
Lepor 1998 (17,18)
Narayan 1998 (31)
Tamsulosin
1.59 (95% CI = 0.92–2.26)
Mohanty 2003 (32)
Abrams 1995 (28) + Chapple 1996 (29)
van Kerrebroeck (AFORTI) 2000 (23)
Roehrborn (ALFUS) 2001 (24)
ALFOTAM – alfuzosin (25)
Roehrborn (ALTESS) 2006 (26)
Alfuzosin
08 4( 9 5 %C I=05 5 – 11 3 )
Roehrborn 2005 (Dox GITS) (39)
Andersen 2000 (Dox GITS) (40)
Janknegt 1993 (Netherlands) (41)
.= . .
Doxazosin GITS 
1.76 (95% CI = 1.23–2.39)
Christensen 1993 (42)
Fawzy 1995 (44)
Andersen 2000 (Dox) (40)
Doxazosin 
Kirby (PREDICT) 2003 (10)
Chapple 1994 (43)
Lepor 1992 (33)
Lepor 1992 (34)
Lloyd 1992 (35)
Brawer 1993 (36)
Roehrborn 1996 (11)
Elhilali 1996 (37)
1.73 (95% CI = 1.26–2.21)
Lepor 1996 (38)
Terazosin
1.27 (95% CI = 0.91–1.63)
6 3 0 –3
Odds ratio (95% confidence interval)
Figure 5 Weighted mean difference of a1-adrenergic receptor blockers in maximum urinary ﬂow rate from placebo
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